Masaki Ishikawa

TL;DR: It is demonstrated that 2ccPA protected oligodendrocytes via suppression of the mitochondrial apoptosis pathway and may be a promising compound for the development of new drugs to treat demyelinating disease and ameliorate the symptoms of multiple sclerosis.

TL;DR: Baicalein treatment attenuated cuprizone-induced demyelination, glial activation, pro-inflammatory cytokine expression, and motor dysfunction, suggesting that Baicalsein may be a useful therapeutic agent in demyELinating diseases to suppress neuroinflammation.

TL;DR: A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based quantification method for the simultaneous detection of cPA species having various fatty acids as well as 2-carba-cPA, a chemically synthesized analog of c PA, revealed to be significantly reduced in the brains of cuprizone-treated mice, a model of multiple sclerosis.

TL;DR: The findings on the effect of the continuous release of 2ccPA from the capsule to reduce the lysophospholipase D activity and also decrease plasma levels of lysphosphatidic acid in rat are presented.

TL;DR: After publication of the article [1], it was brought to the attention that an acknowledgement was missing from the original version.